Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.50 |
| ▸ | CCR1 | P32246 | 10/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7949042 | 0.93 | CCR1 (0.52) | DRD2CCR1 | |
| SCHEMBL8568579 | 0.87 | OPRM1 (0.58) | DRD2CCR1HTR1ADRD4HRH2 | |
| SCHEMBL7960074 | 0.85 | DRD2 (0.62) | DRD2CCR1 | |
| SCHEMBL7957164 | 0.84 | DRD2 (0.56) | DRD2CCR1 | |
| SCHEMBL7963905 | 0.83 | DRD2 (0.59) | DRD2HTR1ADRD4HRH2HTR2A | |
| SCHEMBL7961470 | 0.82 | DRD2 (0.49) | DRD2CCR1 | |
| SCHEMBL7963515 | 0.82 | CCR1 (0.58) | DRD2CCR1 | |
| SCHEMBL7949619 | 0.81 | DRD2 (0.53) | DRD2CCR1HTR1AHTR2AHRH1 | |
| SCHEMBL7960233 | 0.81 | CCR1 (0.54) | DRD2CCR1DRD4 | |
| SCHEMBL7959911 | 0.80 | CCR1 (0.45) | DRD2CCR1HTR1ADRD4HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6187774-B1 | N-PIPERAZINYLALKYLINDAZOLE DERIVATIVES; PSYCHOLOGICAL DISORDERS, SCHIZOPHRENIA; SIDE EFFECT REDUCTION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2001-02-13 | — | — | US | disclosed |
| EP-0885883-A1 | FUSED HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-12-23 | — | — | EP | disclosed |